Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation

Turun Song†, Saifu Yin†, Yamei Jiang, Zhongli Huang, Jinpeng Liu, Zhiling Wang, Linde Li, Jun Zeng, Yu Fan, Xianding Wang, Xingxing Li and Tao Lin*

Urology Department, Urology Research Institute, Organ Transplantation Centre, West China Hospital, Sichuan University, Chengdu, China

Background: The aim of the present study was to investigate the impact of time in therapeutic range TTR on long-term outcomes of living kidney transplants.

Methods: We included 1,241 living kidney transplants and randomized them into development and validation cohorts with a ratio of 2:1. The tacrolimus TTR percentage was calculated by linear interpolation with a target range (5–10 ng/ml months 0–3, 4–8 ng/ml months 4–12). The optimal TTR cutoff was estimated by the receiver operating characteristic curve analysis on the basis of acute rejection (AR) within 12 months in the development cohort. Outcomes were analyzed between patients with high TTR and low TTR in the development and validation cohorts, respectively. The TTR was also compared with other tacrolimus measures.

Results: The optimal TTR cutoff value was 78%. In the development cohort, patients with TTR > 78% had significantly higher rejection- and infection-free survival. TTR < 78% was an independent risk factor for AR (OR: 2.97, 95%CI: 1.82–4.84) and infection (OR: 1.55, 95%CI: 1.08–2.22). Patient and graft survival were significantly higher in those with TTR>78%, and TTR<78% was associated with graft loss (OR: 3.2, 95%CI: 1.38–7.42) and patient death (OR: 6.54, 95%CI: 1.34–31.77). These findings were confirmed in the validation cohort. Furthermore, we divided all included patients into a high and low TTR group. TTR was more strongly associated with patient and graft survival than mean level, standard deviation, and intrapatient variability (IPV).

Conclusions: Increasing the TTR of tacrolimus in the first year was associated with improved long-term outcomes in living kidney transplants, and TTR may be a novel valuable strategy to monitor tacrolimus exposure.

Keywords: tacrolimus, time in therapeutic range, kidney transplantation, development and validation, acute rejection, infection, graft loss, patient death

INTRODUCTION

Tacrolimus-based regimens are the most commonly used immunosuppressive therapies, preventing T-cell and antibody-mediated rejection after kidney transplantation (1); however, a narrow therapeutic index limited their clinical application. Overexposure can result in toxicity and severe infection, and underexposure can lead to graft rejection (2, 3). Therapeutic drug
monitoring to maintain the intensity and stability and a constant tacrolimus trough level allows for the achievement of optimal immunosuppression. Mean level, intrapatient variability (IPV), and variability of the standard deviation of the tacrolimus trough level are associated with acute rejection (AR) and graft loss (4–6). However, these indexes did not consider whether the tacrolimus trough level achieved a target therapeutic window and exposure time. As failure to maintain the tacrolimus trough level in target ranges is a risk factor for inferior short- and long-term outcomes (7, 8), it seems more practical and clinically relevant to develop a new indicator to combine the tacrolimus trough level with variation and the corresponding maintaining time.

Percent time in therapeutic range (TTR), defined as the percentage of time within the therapeutic range over time, takes stability, intensity, and constancy into consideration simultaneously. TTR is a validated method for assessing effective warfarin therapy and has been used as a tool to risk stratifying (9, 10). Limited studies have investigated the use of TTR in transplantation, but a low tacrolimus TTR was associated with significantly increased acute cellular risk in lung transplants (11) and de novo donor-specific antibodies (dnDSAs) in kidney transplants (12). These facts indicated that the tacrolimus TTR might have potential as a prognostic indicator in organ transplantation, but evidence of its impact on the long-term outcomes of living kidney transplants is lacking. The present study investigated whether patients with a high tacrolimus TTR had better clinical results than those with a low tacrolimus TTR.

METHODS

Patient Population

The clinical data of patients who received a living-related kidney transplant at West China Hospital between August 2007 and April 2017 were retrospectively analyzed. The Ethics Committee of West China Hospital approved the study. Patients who were <18 years of age, with an initial calcineurin inhibitor (CNI) other than tacrolimus, tacrolimus switch or withdrawal in first 12 months, receiving an ABO-incompatible kidney transplant, with organ transplant history, a follow-up of <1 year, or with three or more consecutive missing measures of tacrolimus trough level, according to our monitoring protocol, were excluded.

Data Collection

We retrieved information from medical records, including patient age, sex, body mass index at the time of transplantation, duration of pretransplantation dialysis, organ transplant history, panel reactive antibody (PRA), human leukocyte antigen (HLA) mismatch, induction therapy, delayed graft function (DGF), and cold ischemic time. DGF was defined as the need for dialysis in the first week after transplantation. AR, infection, graft loss, and patient death were the clinical outcomes of interest. AR was diagnosed clinically based on a 50% or more significant increase in serum creatinine levels within 3 days that was not explained by some other cause and that was confirmed by biopsy when necessary. AR was treated primarily with bolus doses of methylprednisolone and with antithymocyte globulin if refractory. Infection was defined as any infectious symptoms needing medication intervention, including wound, pulmonary, urinary tract, and skin infections. Re-establishment of long-term dialysis therapy or estimated glomerular filtration rate (eGFR) of <15 ml/min was considered as graft loss. Allograft survival was censored at the earliest of the following events: loss to follow-up or patient death. The definition of graft failure did not include patient death with a functioning graft. Renal function was assessed by eGFR, calculated using the Modification of Diet in Renal Disease (MDRD) equation for Chinese and adjusted for body surface area (13).

Immunosuppression Regimen

The immunosuppression therapy used at our hospital has been previously described (14). Briefly, rabbit antihuman thymocyte immunoglobulin (ATG) (1 mg/kg administered for 3–7 days) or monoclonal anti-CD25 monoclonal antibody (IL-2R antibody) (20 mg on days 0 and 4 post-transplant) were used as induction therapy. Maintenance immunosuppressive therapy consisted of tacrolimus, mycophenolate mofetil/enteric-coated mycophenolate sodium (MMF/EC-MPS), and corticosteroids. Tacrolimus was initiated at 1.5 mg bid on day two post-transplantation and maintained at 5–12 ng/mL. The tacrolimus trough level was measured by the enzyme multiplied immunoassay technique (EMIT, Dade-Behring, NY, USA) in blood samples collected weekly during months 0–3, every 2 weeks during months 4–6, and monthly thereafter in the first year. Tacrolimus trough levels were obtained before breakfast and dose administration in the morning. Any tacrolimus levels that were <2 or > 15 ng/mL were individually reviewed and excluded if they were not valid. MMF was started on the night before the operation at 1,000 mg and maintained at 1,000 mg bid. The area under the curve (AUC) for mycophenolate mofetil was 30–70 mg·h·L\(^{-1}\). EC-MPS 720 mg was administrated the night before the operation and at 720 mg bid after that. The EC-MPS AUC was not measured. Methylprednisolone 500 mg was administered intravenously during the surgery, and 300 mg was given daily for the next 3 days. It was then replaced by 60 mg of prednisone, which was tapered by 10 to 5–10 mg/day for maintenance.

Time in Therapeutic Range

We randomized all patients into development and validation cohorts with a ratio of 2:1. The process was finished by SPSS 24.0 software. First, SPSS gave each individual a random number. Then, these number were ranked in order from large to small. Last, the first 2/3 was used as the developed cohort and the latest 1/3 was used as the validation cohort. The tacrolimus TTR percentage was calculated by linear interpolation as described by Rosendaal in the development cohort (15). The linear relationship between each tacrolimus trough level and the TTR was calculated by summing the time during which the value fell within the target tacrolimus range of 5–10 ng/ml during months 0–3 and 4–8 ng/ml during months 4–12. The tacrolimus TTR was compared with the tacrolimus standard deviation (SD), mean, and the IPV. The IPV was calculated by dividing SD by the mean level (16).
**Statistical Analysis**

Descriptive statistics were used to describe the baseline characteristics of the patients in the development and validate cohorts. Categorical variables were compared using the \( \chi^2 \)-test or Fisher’s exact test; continuous variables were compared using a Student’s \( t \)-test. A receiver operating characteristic (ROC) curve was built from the calculated TTR value in development cohort to determine the optimal TTR cutoff value that can discriminate patients with or without AR in the first year best. The area under the ROC curve with sensitivity and specificity was computed, and the TTR with the greatest AUC is the optimal cut-off value (17).

Time to AR, infection, graft loss, and recipient death was analyzed by the Kaplan–Meier method, and between-group differences were assessed for significance by the log-rank test. Cox Proportional regression was used to identify predictors of AR, infection, graft loss, and patient death. Variables with \( p < 0.1 \) in the univariate analysis were included in the multivariate analysis. The statistical analysis was performed using SPSS 24.0 (IBM Corp., Armonk, NY, USA). \( P < 0.05 \) was considered significant.

**RESULTS**

From August 2007 to April 2017, 2,048 patients received a living related kidney transplant in West China Hospital, Sichuan University. A total of 807 patients were excluded: follow-up time was <1 year \((N = 227)\); CNI was not tacrolimus \((N = 275)\); lost in the follow-up \((N = 82)\); organ transplantation history \((N = 15)\); ABO-incompatible kidney transplantation \((N = 38)\); and consecutive missing of tacrolimus trough level 3 times or more \((N = 170)\). A total of 1,241 patients were included with 827 in the development cohort and 414 in the validation cohort. The process of enrollment of patients is shown in the flow chart (Supplementary Figure 1). The clinical characteristics of the development cohort and validation cohort are shown in Table 1. The median follow-up for the entire cohort was 42 months [interquartile range (IQR): 26–59 months]; 42 months (IQR: 26–59 months) for the development cohort, and 42 months (IQR: 25–59 months) for the validation cohort.

The optimal cutoff value for TAC TTR was 78% (AUC = 0.733; sensitivity = 66.3%; and specificity = 69.1%) (Figure 1). We thus divided patients in the development and validation cohort into a high TTR group and low TTR group. Baseline characteristics between the high and low TTR groups in both cohorts are summarized in Table 2. All variables were comparable between high and low TTR groups in the development cohort; however, in the validation cohort, patients in the low TTR group received kidneys from older donors \((P = 0.02)\) and had more HLA mismatches \((P = 0.02)\). There was no difference in the tacrolimus trough levels between high and low TTR groups within the first year in the development and validation cohort. No difference was detected in renal function between the two groups during the follow-ups in the development cohort, while the high TTR group in validation cohort had a litter higher eGFR in first 3 years (mean difference 4~5 ml/min/1.73 m²) (Figure 2).

**Graft Survival**

In the development cohort, more patients experienced graft loss \((15/283, 5.3\%)\) in the low TTR group than those in the high TTR \((9/544, 1.7\%)\) \((P < 0.001)\). The Kaplan–Meier curve indicated

---

**TABLE 1 | Clinical characteristics of the development cohort and validation cohort.**

| Characteristics | Development \((N = 827)\) | Validation \((N = 414)\) | \(P\)-value |
|-----------------|--------------------------|---------------------------|-------------|
| Donor age (years) | 47.3 (±9.8) | 47.4 (±9.7) | 0.88 |
| Donor sex (Male) | 33.00% | 31.50% | 0.72 |
| Donor eGFR | 109.4 ± 13.7 | 115.6 ± 17.5 | 0.63 |
| Recipient age (years) | 33.1 (±8.3) | 32.7 (±8.7) | 0.43 |
| Recipient sex (Male) | 71.70% | 71.90% | 0.95 |
| Recipient BMI, Kg/m² | 21.5 (±3.5) | 21.8 (±1.8) | 0.72 |
| Cold ischemic time (h) | 2.5 (±0.9) | 2.5 (±0.9) | 0.88 |
| DGF | 1.10% | 1.50% | 0.48 |
| Induction therapy | 46.00% | 48.00% | 0.72 |
| No | 33.90% | 31.60% | 0.11 |
| ATG | 11.95% | 10.60% | 0.46 |
| IL-2 R antibody | 54.20% | 57.90% | 0.11 |
| HLA mismatches | &lt;3 mismatch | 11.50% | 15.00% | 0.95 |
| &gt; 3 mismatch | 88.50% | 85.00% | 0.95 |
| Pre-transplant PRA &gt; 20% | 2.90% | 2.90% | 0.95 |
| Duration of dialysis, months | 13.4 (±14.8) | 13.4 (±15.8) | 0.94 |
| Transplant year | 2007–2012 | 140 | 0.56 |
| 2013–2017 | 561 | 274 |

\(\text{ATG, antithymocyte globulin; BMI, body mass index; eGFR, estimated glomerular filtration rate; DGF, delayed graft function; HLA, human leukocyte antigen; PRA, panel reactive antibody.}\)

\(\text{aContinuous data are presented as mean ± standard deviation (SD), and categorical data as percentage of the total, unless otherwise noted.}\)
### TABLE 2 | Characteristics between the high and low TTR groups in development and validation cohorts.

| Characteristics                  | Development                        | Validation                        |
|----------------------------------|------------------------------------|-----------------------------------|
|                                  | TTR<78% (N = 283)                  | TTR>78% (N = 544)                 | TTR<78% (N = 145)                  | TTR>78% (N = 269) |
| Donor age (years)                | 46.8 (±10.2)                       | 47.7 (±9.5)                       | 46 (±9)                           | 48.5 (±9.8)       | 0.09 |
| Donor sex (Male)                 | 30.70%                             | 32.70%                            | 28.20%                           | 36.90%            | 0.22 |
| Donor eGFR                       | 111.3 ± 11.6                       | 108.4 ± 14.9                      | 118.6 ± 20.8                     | 114.0 ± 11.8      | 0.57 |
| Recipient age (years)            | 32.9 (±8.7)                        | 32.8 (±8.5)                       | 34.4 (±8.5)                      | 32.4 (±8.1)       | 0.02 |
| Recipient sex (Male)             | 72.00%                             | 71.80%                            | 71.05%                           | 72.10%            | 0.81 |
| Recipient BMI, kg/m²             | 21.4 (±3)                          | 21.9 (±18)                        | 21.5 (±3)                        | 21.4 (±3.7)       | 0.74 |
| Cold ischemic time (h)           | 2.5 (±0.9)                         | 2.6 (±0.9)                        | 2.5 (±0.9)                       | 2.6 (±0.9)        | 0.52 |
| DGF                              | 1.40%                              | 1.00%                             | 1.30%                            | 1.60%             | 0.37 |
| Induction therapy                |                                    |                                   |                                   |                   | 0.21 |
| No                               | 35.50%                             | 29.70%                            | 37.90%                           | 31.30%            |       |
| ATG                              | 9.20%                              | 11.30%                            | 13.80%                           | 10.80%            |       |
| IL-2 R antibody                  | 55.30%                             | 59.00%                            | 48.30%                           | 57.80%            |       |
| HLA mismatches                   |                                    |                                   |                                   |                   | 0.02 |
| ≤3 mismatch                      | 86.20%                             | 78.70%                            | 82.60%                           | 90.90%            |       |
| >3 mismatch                      | 13.80%                             | 21.30%                            | 17.40%                           | 9.10%             |       |
| Pre-transplant PRA >20%          | 3.00%                              | 2.80%                             | 2.80%                            | 2.60%             | 0.93 |
| Duration of dialysis, months     | 13.2 (±14.9)                       | 13.5 (±15.8)                      | 14.4 (±15.7)                     | 12.8 (±14.3)      | 0.29 |
| Transplant year                  |                                    |                                   |                                   |                   | 0.52 |
| 2007–2012                        | 87                                 | 179                               | 52                               | 88               |       |
| 2013–2017                        | 196                                | 365                               | 93                               | 181              |       |

ATG, antithymocyte globulin; BMI, body mass index; eGFR, estimated glomerular filtration rate; DGF, delayed graft function; HLA, human leukocyte antigen; PRA, panel reactive antibody.

### FIGURE 2 | Average tacrolimus concentration and eGFR distribution in the development and validation cohort at different time point.

(A) Tac concentration in the development cohort; (B) Tac concentration in the validation cohort; (C) eGFR in the development cohort; (D) eGFR in the validation cohort. Tac, tacrolimus.
FIGURE 3 | The Kaplan-Meier curves of the rejection-free survival (A), infection-free survival (B), graft survival (C), and patient survival (D) in the development cohort.
that the graft survival in the high TTR group was significantly higher than that in the low TTR group (Figure 3C). The 3- and 5-year graft survival was 97.5 and 96.6% as well as 93.5 and 92.3% for the high and low TTR group, respectively. Lower TTR was an independent graft-loss contributor in the multivariate analysis (OR: 3.2, 95%CI: 1.38–7.42). A younger age also seemed to be protective for graft survival (OR: 0.95, 95%CI: 0.90–1.00) (Table 3).

Similarly, in the validation cohort, more patients have experienced graft loss (6.2 vs. 2.6%, P = 0.069) in the low TTR group. Kaplan-Meier estimation indicated graft survival in high TTR group was significantly higher than that in low TTR group (Figure 4). Lower TTR was associated with a higher risk of graft loss (OR: 5.09, 95%CI: 1.28–23.65). Also, younger recipients (OR: 0.87, 95%CI: 0.78–0.96) and lower PRA (OR: 0.07; 95%CI: 0.01–0.56) were found to have independent protective effects on graft survival (Table 4).

Recipient Survival
In the development cohort, during the follow-up, 7 (2.5%) and 2 deaths (0.4%) were recorded in the low TTR group and high TTR group (P = 0.016), respectively. The Kaplan–Meier estimation found that the high TTR group had significantly better patient survival than that of low TTR group (Figure 3D). The 3- and 5-year graft survival was 99.2 and 99.2% as well as 97.2 and 94.8% for the high and low TTR group, respectively. Lower TTR was an independent risk factor for graft loss in the multivariate analysis (OR: 6.54, 95%CI: 1.34–31.77) (Table 3).

In the validation cohort, a similar trend was observed with more patients experiencing patient death (4.1 vs. 0.7%, P = 0.043) in the low TTR group. Lower TTR was associated with a higher risk of patient death (OR: 6.8, 95%CI: 1.34–34.61) (Table 4). The Kaplan–Meier estimation indicated patient survival in the high TTR group was significantly higher (Figure 4).

Acute Rejection
In the development cohort, 44 patients (15.5%) developed AR in the low TTR group compared to 32 (5.9%) in the high TTR group (P < 0.001). Patients without developing DGF (OR: 0.21, 95%CI: 0.06–0.77) were also observed to develop less AR. A multivariate analysis indicated that TTR ≤ 78% was an independent risk factor for AR (OR: 2.97, 95%CI: 1.82–4.84) (Table 3). Rejection-free survival was significantly higher in the high TTR group than that in the low TTR group (Figure 3).

In the validation group, similar results were observed. There were significantly more patients experiencing AR (12.4 vs. 2.6%, P < 0.001) in the low TTR group. Multivariate regression showed that TTR ≤ 78% was associated with a higher incidence of AR (OR: 2.97, 95%CI: 1.82–4.84) (Table 4). The Kaplan–Meier estimation indicated that rejection-free survival was significantly higher in the high TTR group than that in the low TTR group (Figure 4).

Infection
For the development cohort, a total of 148 patients developed infection at least once with 63 (22.3%) in the low TTR group and 85 (15.6%) in the high TTR group (P = 0.018). Low TTR was associated with a higher risk of infection in the multivariate analysis (OR: 1.55, 95%CI: 1.08–2.22) (Table 3). The Kaplan–Meier estimation revealed that the infection-free survival was significantly higher in the high TTR group than that in the low TTR group (Figure 3).

Furthermore, in the validation group, we confirmed the results that more patients experienced infection episodes (24.1 vs. 13.8%, P = 0.008) in the low TTR group. TTR ≤ 78% was associated with a higher incidence of infection (OR: 2.00, 95%CI: 1.19–3.34) in the multivariate regression (Table 4). Infection-free survival in the Kaplan–Meier curve was significantly higher in the high TTR group than that in the low TTR group (Figure 4).

Comparison to Other Tacrolimus Measures
Multivariate regression was also used to examine alternative measures for the characterization of tacrolimus exposure. We separated 1,241 patients into high and low TTR groups by TTR cut-off value. In 1,241 patients overall, increasing the TTR by 10% was associated with reduced patient death (OR = 0.73, 95%CI: 0.63–0.86) and graft loss (OR = 0.53, 95%CI: 0.36–0.80) (Table 5). Increasing IPV was an independent risk factor for graft loss, and all alternative tacrolimus measures were predictors for patient death. However, none of the tacrolimus measures were significantly associated with patient and graft survival in the high TTR group. In the low TTR group, increasing TTR by 10% remained independently protective for both patient (OR = 0.60, 95%CI: 0.40–0.93) and graft survival (OR = 0.51, 95%CI: 0.28–0.92). Only increasing IPV was associated with a higher incidence of graft loss (OR = 1.04, 95%CI: 1.01–1.07).

DISCUSSION
To the best of our knowledge, this is the first study to assess the effect of tacrolimus TTR on long-term outcomes in living kidney transplantation. In the current study, we found that a TTR above 78% was not only associated with improved graft survival but also with reduced risk of AR and infection. Tacrolimus TTR was more strongly associated with patient and graft survival than mean level, standard deviation (SD), and IPV.

The first reported use of TTR was for the therapeutic use of warfarin, a drug with considerable inter- and intra-patient variability and a narrow therapeutic index, much like tacrolimus. The warfarin TTR cut-off value was arbitrarily determined as 75% (10) or was recommended by European guidelines as being 70% or greater (18). Two studies investigating the use of tacrolimus TTR also arbitrarily set the TTR threshold as 30% in lung transplant (11) or 60% in kidney transplant (12). Although they found that increasing tacrolimus TTR was associated with improved clinical outcomes, the optimal TTR was not determined. The primary aim of maintaining the tacrolimus within the therapeutic range is to control rejection, and so we utilized the ROC curve to estimate the optimal TTR value based on the AR episodes in the first year. The cut-off value was 78%, and the AUC was 0.733. Though the AUC value was fair, the TTR of 78% can differentiate patients with increased risk of graft failure and patient death in the development group very well. Additionally, we further validated the TTR cut-off and its
### TABLE 3 | Univariate and Multivariate analysis of clinical characteristics for acute rejection, infection, and patient and graft survival in development cohort.

| Characteristic          | Acute rejection | Infection | Graft survival | Patient survival |
|-------------------------|-----------------|-----------|----------------|-----------------|
|                         | Unadjusted P    | Adjusted P | P  | Unadjusted P | Adjusted P | P  | Unadjusted P | Adjusted P | P  | Unadjusted P | Adjusted P | P  |
| TTR                     | 3.36 (2.21–5.11) | 1.55 (1.08–2.22) | 0.019 | 1.55 (1.06–2.22) | 0.019 | 3.33 (1.44–7.7) | 0.005 | 3.2 (1.38–7.42) | 0.007 | 6.87 (1.42–33.31) | 0.017 | 6.54 (1.34–31.77) | 0.02 |
| Donor age               | 1.01 (0.98–1.04) | 0.99 (0.99–1.05) | 0.019 | 1.02 (0.99–1.06) | 0.019 | 1.02 (0.96–1.09) | 0.019 | 0.44 (0.05–3.78) | 0.019 | 1.02 (0.94–1.11) | 0.019 |
| Donor sex               | 0.67 (0.34–1.32) | 0.99 (0.31–1.13) | 0.019 | 0.59 (0.31–1.13) | 0.019 | 1.27 (0.36–4.43) | 0.019 | 0.44 (0.05–3.78) | 0.019 | 0.44 (0.05–3.78) | 0.019 |
| Recipient age           | 0.98 (0.96–1.01) | 0.99 (0.97–1.01) | 0.019 | 0.99 (0.97–1.01) | 0.019 | 1.18 (0.46–3) | 0.019 | 0.44 (0.05–3.78) | 0.019 | 3.15 (0.39–25.35) | 0.019 |
| Recipient sex           | 1.21 (0.76–1.93) | 0.99 (0.77–1.72) | 0.019 | 1.15 (0.77–1.72) | 0.019 | 0.96 (0.91–1.01) | 0.019 | 1.28 (0.98–1.03) | 0.019 | 1.28 (0.98–1.03) | 0.019 |
| Recipient BMI           | 0.99 (0.93–1.05) | 0.99 (0.97–1.02) | 0.019 | 0.99 (0.97–1.02) | 0.019 | 0.96 (0.81–1.13) | 0.019 | 1.28 (0.98–1.03) | 0.019 | 1.28 (0.98–1.03) | 0.019 |
| Time of dialysis        | 1 (0.98–1.01) | 1 (0.99–1.01) | 0.019 | 1 (0.99–1.01) | 0.019 | 1 (0.98–1.03) | 0.019 | 1 (0.99–1.04) | 0.019 | 1 (0.99–1.04) | 0.019 |
| DGF                     | 0.21 (0.07–0.7) | 0.21 (0.06–0.77) | 0.018 | 0.21 (0.06–0.77) | 0.018 | 0.43 (0.13–1.44) | 0.018 | 0 | 0 |
| HLA mismatch            | 1.49 (0.7–3.2) | 0.99 (0.59–1.65) | 0.018 | 0.99 (0.59–1.65) | 0.018 | 1.93 (0.45–8.3) | 0.018 | 1.38 (0.17–11.17) | 0.018 | 1.38 (0.17–11.17) | 0.018 |
| PRA                     | 1.17 (0.27–5.06) | 0.83 (0.39–3.4) | 0.018 | 0.83 (0.39–3.4) | 0.018 | 0.71 (0.09–5.47) | 0.018 | 0 | 0 |
| Cold ischemic time      | 0.73 (0.55–0.95) | 0.02 (0.98–1.01) | 0.018 | 0.92 (0.75–1.13) | 0.018 | 0.96 (0.63–1.58) | 0.018 | 0.48 (0.21–1.1) | 0.018 | 0.48 (0.21–1.1) | 0.018 |
| Induction therapy       | 0.15 (Reference) | 0.254 (Reference) | 0.018 | 0.254 (Reference) | 0.018 | 0.297 (Reference) | 0.018 | 0.838 (Reference) | 0.018 | 0.838 (Reference) | 0.018 |

ATG, antithymocyte globulin; BMI, body mass index; eGFR, estimated glomerular filtration rate; DGF, delayed graft function; HLA, human leukocyte antigen; PRA, panel reactive antibody; TTR, time in therapeutic range.
FIGURE 4 | The Kaplan–Meier curves of the rejection-free survival (A), infection-free survival (B), graft survival (C), and patient survival (D) in the validation cohort.
| Characteristic         | Acute rejection | Infection | Graft survival | Patient survival |
|------------------------|-----------------|-----------|----------------|-----------------|
|                        | Unadjusted P    | Adjusted P| Unadjusted P   | Adjusted P      | Unadjusted P | Adjusted P | Unadjusted P | Adjusted P |
| TTR                    | 5.3 (2.16–13.03) | <0.001    | 5.36 (2.17–13.21)| <0.001 | 2 (1.19–3.34) | 0.009  | 2 (1.19–3.34) | 0.009  | 2.66 (0.96–7.46) | 0.064  | 5.09 (1.28–23.65) | 0.022  | 5.76 (1.15–28.93) | 0.033  | 6.8 (1.34–34.61) | 0.021  |
| Donor age              | 1.01 (0.95–1.08) | 0.731     | 0.99 (0.95–1.04) | 0.751 | 0.95 (0.89–1.01) | 0.085  | 0.93 (0.86–1)  | 0.066  | 0.92 (0.84–1.01) | 0.086  | 0.91 (0.82–1.01) | 0.089  |
| Donor sex              | 0.64 (0.17–2.47) | 0.521     | 0.81 (0.33–1.97) | 0.643 | 0.69 (0.21–2.26) | 0.538  | 0.92 (0.82–1)  | 0.064  | 0.92 (0.82–1)  | 0.064  | 0.92 (0.82–1)  | 0.064  |
| Recipient age          | 1 (0.95–1.05)   | 0.965     | 1 (0.97–1.03)   | 0.9    | 0.88 (0.8–0.96)  | 0.07   | 0.066 (0.83–1.03) | 0.93  | 0.93 (0.83–1.03) | 0.145  |
| Recipient sex          | 0.68 (0.29–1.59) | 0.378     | 1.34 (0.74–2.42) | 0.336 | 2.84 (0.64–12.71)| 0.171  | / /  | / /  | / /  |
| Recipient BMI          | 0.91 (0.79–1.06) | 0.222     | 1.01 (0.93–1.1) | 0.769 | 1.02 (0.87–1.19) | 0.815  | 1.01 (0.81–1.25) | 0.957  |
| Time of dialysis       | 0.97 (0.93–1.01) | 0.157     | 0.99 (0.98–1.01)| 0.524 | 0.97 (0.91–1.03) | 0.26   | 0.98 (0.92–1.05) | 0.566  |
| DGF                    | / /             | / /       | / /            | / /   | / /            | / /    | / /  | / /  | / /  |
| HLA mismatch           | 0.67 (0.22–2.04) | 0.477     | 0.93 (0.43–2.02) | 0.881 | 0.96 (0.21–4.35) | 0.96   | 0.96 (0.12)   | 0.969  |
| PRA                    | 0.27 (0.06–1.33) | 0.109     | 0.25 (0.05–1.36) | 0.109 | 0.27 (0.03–0.82) | 0.16   | 0.028 (0.01–0.56) | 0.013  | 0.18 (0.02–1.58) | 0.12   |
| Cold ischemic time     | 1.14 (0.72–1.79) | 0.575     | 1.06 (0.8–1.4)  | 0.704 | 0.92 (0.53–1.8)  | 0.759  | 0.97 (0.45–2.1) | 0.936  |
| Induction therapy      | 0.334           |          |                |        | 0.578           | 0.347  | 0.237 |
| No ATG                 | 1.85 (0.76–4.47) |          |                |        | 2.23 (0.76–6.57) | 4.16   | / /  |
| IL-2R                  | 1.91 (0.57–6.37) |          |                |        | 1.55 (0.3–7.94)  | 2.32   | / /  |
| Transplant year        | 0.21            |          |                |        | 0.73            | 0.32   | 0.63 |
| 2007–2012 Reference    | Reference        |          |                |        | Reference       | Reference |
| 2013–2017             | 0.76 (0.51–1.13) |          |                |        | 0.96 (0.82–1.13) | 0.85   | 0.92 |

ATG, antithymocyte globulin; BMI, body mass index; eGFR, estimated glomerular filtration rate; DGF, delayed graft function; HLA, human leukocyte antigen; PRA, panel reactive antibody; TTR, time in therapeutic range.
role as an informative predictor in the validation cohort. Of note was the fact that, to accurately estimate TTR, we excluded cases with three or more consecutive missing values of tacrolimus. As the TTR was calculated by the Rosendaal method, which assumed a linear relationship exists between each measured value, that linear interpolation method was used to estimate the missing values (15). When there are three or more consecutive missing values, it is not reliable to apply interpolation, and this is due to the limitation of this technique.

We found that a higher tacrolimus TTR was strongly associated with better graft survival and rejection-free survival. These observations were consistent with the findings from previous kidney transplant and lung transplant analyses, which used the TTR to characterize tacrolimus exposure (11, 12). Notably, we did not find any difference in mean tacrolimus trough level between the high and low TTR groups. However, the high TTR group had much lower SD (1.9 vs. 1.4) and IPV (24.1 vs. 34.2%) of tacrolimus levels than that in low TTR group. Together with the facts that increasing SD and IPV of tacrolimus levels are independent risk factors for rejection and graft loss (6, 19), a higher TTR can thus predict better outcomes.

Interestingly, we found that TTR > 78% was associated with reduced infection, which was corroborated by the lung transplant study that found that increasing the TTR by 10% was associated with a decreased likelihood of infection (OR 0.81, 95%CI: 0.67–0.97) (11). We previously found that the increasing tacrolimus trough level at the first month was associated with infection, and those that had a tacrolimus trough level >7.15 ng/ml experienced a much higher incidence of infection (20). In the high TTR group, of 9,756 tacrolimus measures in 12 months, 8.0% had level >8 ng/ml, significantly lower than that in the low TTR group (14.4%, p < 0.001). Similar findings were confirmed in the first 3 months (3.2 vs. 6.4%, p < 0.001), indicating that the low TTR group had more patients with over-immunosuppression. Thus, the low TTR group may have a higher incidence of infection. However, when infection is diagnosed, a dose reduction is usually required. That erratic change of the tacrolimus level will result in a lower TTR.

The effects of several tacrolimus exposure characteristics have been investigated in kidney transplantation. A single measurement of an increased tacrolimus trough level soon after a kidney transplant has been associated with a decreased risk of AR and biopsy-proven AR (21, 22). However, a single time-point measurement may not be meaningful because tacrolimus trough levels are produced by dynamic rather than stable metabolic processes. Recently, a pooled analysis across four randomized trials found that the average tacrolimus level in first 12 months <4.0 ng/ml was associated with an increased incidence of BPAR (HR = 6.33, p < 0.00001) (7). Sapir-Pichhadze et al. conducted a retrospective cohort investigation of kidney transplants, examining the effect of the SD of tacrolimus levels on the composite endpoint (late allograft rejection, glomerulopathy, and total graft loss). They found that, for every 1-unit increase in SD, there was a 27% increase in the adjusted hazard of the composite endpoint (HR 1.27, 95%CI: 1.03–1.56) (6). Additional study using the mean level and SD to characterize tacrolimus exposure yielded similar findings (23, 24). Importantly, we found that the tacrolimus TTR was more strongly associated with patient and graft survival than mean level and SD. A subgroup analysis of the high TTR group found the predictive effect of all alternative measures disappeared. SD may poorly characterize levels that are consistently above or below the target range, and mean value cannot differentiate erratic changes between high and low levels, but TTR accounts for the concentration, variability, and the time between levels simultaneously. Together with our finding that a higher TTR can eliminate a large part of SD (1.4 vs. 1.9, p < 0.001), we found that that the TTR may better characterize exposure compared to the mean value and SD.

Increasing the IPV of tacrolimus is also a risk factor for inferior graft survival. In a retrospective analysis of 310 adult kidney transplants, an IPV >30% independently related to death censored graft loss (HR = 2.613, 95%CI: 1.361–5.016) and dnDSAs (HR = 2.925, 95%CI: 1.473–5.807) (25). However, we found the high TTR group had a much lower IPV than that in low TTR group (24 vs. 34%, p < 0.001), and tacrolimus TTR is more strongly associated with patient and graft survival than IPV, indicating that the TTR may be a better index of tacrolimus monitoring. What’s more, the real-time clinical utility of IPV is limited because it cannot be generally computed at the bedside nor making clinical decisions based on the result.

### TABLE 5 | Adjusted Cox regression models for patient and graft survival using different measures of tacrolimus exposure.

|               | Overall patient | High TTR group | Low TTR group |
|---------------|-----------------|----------------|---------------|
|               | Adjusted        | P              | Adjusted      | P              | Adjusted        | P              |
| **GRAFT SURVIVAL** |                 |                |               |                |                 |                |
| Increasing TTR by 10% | 0.73 (0.63–0.86) | <0.001 | 0.91 (0.44–1.91) | 0.809 | 0.60 (0.40–0.93) | 0.02 |
| Increasing mean level | 0.79 (0.55–1.13) | 0.194 | 0.59 (0.26–1.38) | 0.215 | 0.82 (0.45–1.50) | 0.618 |
| Increasing standard deviation | 1.33 (0.66–2.54) | 0.461 | 1.46 (0.06–37.04) | 0.820 | 0.54 (0.14–2.09) | 0.37 |
| Increasing IPV% | 1.05 (1.03–1.07) | <0.001 | 0.77 (0.48–1.24) | 0.278 | 1.04 (1.01–1.07) | 0.003 |
| **PATIENT SURVIVAL** |                 |                |               |                |                 |                |
| Increasing TTR by 10% | 0.53 (0.36–0.80) | 0.002 | 1.16 (0.28–4.88) | 0.836 | 0.51 (0.28–0.92) | 0.026 |
| Increasing mean level | 2.49 (1.08–6.75) | 0.032 | 1.79 (0.36–8.96) | 0.476 | 2.44 (1.14–5.23) | 0.021 |
| Increasing standard deviation | 2.49 (1.06–6.87) | 0.037 | 0.94 (0.13–6.90) | 0.952 | 2.70 (0.81–9.02) | 0.107 |
| Increasing IPV% | 1.06 (1.00–1.13) | 0.06 | 0.32 (0.003–28.87) | 0.671 | 1.05 (0.96–1.16) | 0.299 |

IPV, intra-patient variability; TTR, time in therapeutic range.
The ease of estimating TAC TTR supports its use as a risk-stratification and decision-making tool. Additionally, high IPV is mainly due to non-adherence (26), and the utilization of TTR may also stratify those with a high non-attendance rate in the outpatient clinic. As suggested by studies involving Warfarin, a less frequent dose change and better adherence contributed to a higher TTR level (27). Interventions to minimize the non-adherence, including the timing and dosing, may also improve tacrolimus TTR in kidney transplants and consequently better adherence, including the timing and dosing, may also improve tacrolimus TTR in kidney transplants and consequently better long-term allograft outcomes. In addition, a high-fat meal and administration of CYP3A4-interfering medications had a significant impact on the rate of TAC absorption and metabolism (28, 29), and so avoiding these factors may improve the TTR as well.

There are several limitations when interpreting our results. First, due to its retrospective nature, we could only establish an association between the TTR and the clinical outcomes. These findings should be confirmed with a prospective assessment. Second, tacrolimus was measured at discrete time points, and missing values were estimated by linear interpolation method. Though we excluded those with three or more consecutive missing values, estimated tacrolimus values may not have accurately reflected the real exposures. Third, the cut-off value of the TTR and its predictive role were based on our target range, whether the TTR remains associated with patient and graft survival in other tacrolimus target ranges was unknown. Finally, we only analyzed living kidney transplants; these observations therefore need to be externally validated in other transplant categories, such as deceased donor and ABO-incompatible kidney transplants.

CONCLUSION

Tacrolimus TTR monitoring was predictive in achieving well-managed tacrolimus-based immunosuppression in living kidney transplants. Future prospective investigations should be conducted to confirm these findings.  

REFERENCES

1. Sellarés J, de Freitas DG, Mengel M, Reeve J, Enecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. *Am J Transplant*. (2011) 12:388–99. doi: 10.1111/j.1600-6143.2011.03840.x
2. Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gürkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *N Engl J Med*. (2007) 357:2562–75. doi: 10.1056/NEJMoa067411
3. Naens M, Kuipers DRL, Sarwal M. Calcineurin inhibitor nephrotoxicity. *Clin J Am Soc Nephrol*. (2009) 4:481–508. doi: 10.2215/CJN.04800908
4. Shemesh E, Fine RN. Is calculating the standard deviation of tacrolimus blood levels the new gold standard for evaluating non-adherence to medications in transplant recipients? *Pediatric Transplant*. (2010) 14:940–3. doi: 10.1111/j.1399-3046.2010.01396.x
5. Whalen HR, Glen JA, Harkins V, Stevens KK, Jardine AG, Geddes CC, et al. High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regime. *Transplantation*. (2017) 101:430–6. doi: 10.1097/TP.0000000000001129
6. Sapir-Pichhadze R, Wang Y, Fanure O, Li Y, Kim SJ. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure. *Kidney Int*. (2014) 85:1404–11. doi: 10.1038/ki.2013.465
7. Gaynor JJ, Ciancio G, Guerra G, Sageshima J, Roth D, Goldstein MJ, et al. Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation. *Transplant Int*. (2016) 29:216–26. doi: 10.1111/tiy.12699
8. Zlinská Z, Dedinská I, Breza J Sr, Laca L. Impact of trough levels of tacrolimus on kidney function and graft survival in short and longer periods after renal transplantation. *Transplant Proc*. (2016) 48:2637–43. doi: 10.1016/j.transproceed.2016.06.051
9. Björck F, Renlund H, Lip GY, Wester P, Svensson PJ, Själander A. Outcomes in a warfarin-treated population with atrial fibrillation. *JAMA Cardiol*. (2016) 1:172–80. doi: 10.1001/jamacardio.2016.0199
10. Szummer K, Gasparini A, Eliasson S, Arnlöv J, Qureshi AR, Bårany P, et al. Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction. *J Am Heart Assoc.* (2017) 6:e004925. doi: 10.1161/JAHA.116.004925
11. Ensor CR, Iselass CJ, Harrigan KM, Morrell MR, Moore CA, Shigemura N, et al. Increasing tacrolimus time-in-therapeutic range is associated with

DATA AVAILABILITY STATEMENT

The datasets analyzed in this article are not publicly available. Requests to access the datasets should be directed to kidney5@163.com.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Ethical Committee of West China Hospital, Sichuan University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

TS, SY, and TL participated in research design. TS and SY participated in the writing of the paper. YJ, ZH, JL, ZW, XL, and JZ participated in the data collection and data wash. YF, SY, TS, XW, and LL participated in data analysis.

FUNDING

This study was supported by the Natural Science Foundation of China under Grant Nos. 81870513, 81470980, and 81600584; the 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University under Grant No. ZY2016104; Youth researcher funding of Sichuan University under Grant No. 2017SCU11042; and Research funding of the Sichuan health and family planning commission under Grant Nos. 17PJ159, 18P434, and 18PJ453.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.02912/full#supplementary-material

Supplementary Figure 1 | A flow chart to describe the enrollment of patients.
superior one-year outcomes in lung transplant recipients. *Am J Transplant.* (2018) 18:1527–33. doi: 10.1111/ajt.14723

12. Davis S, Gralla J, Klem F, Tong S, Wedernyger G, Freed B, et al. Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. *Am J Transplant.* (2018) 18:907–15. doi: 10.1111/ajt.14504

13. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y., et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. *J Am Soc Nephrol.* (2006) 17:2937–44. doi: 10.1681/ASN.2006040368

14. Song T, Fu L, Rao Z, Zeng D, Huang Z, Wang X., et al. Kidneys from older living donors provide excellent short and intermediate outcomes—a single china center’s experience. *Transplantation.* (2015) 99:81–8. doi: 10.1097/TP.0000000000000580

15. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. *J Thromb Haemost.* (1993) 69:236–9. doi: 10.1055/s-0038-1651587

16. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. *Nephrol Dial Transplant.* (2010) 25:2757–63. doi: 10.1093/ndt/gfq096

17. Zou KH, O’Malley AJ, Mauri L. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. *Circulation.* (2007) 115:654–7. doi: 10.1161/CIRCULATIONAHA.105.594929

18. DeCaterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin K antagonists in heart disease: current status and perspectives (section III). Position paper of the ESC Working Group on Thrombosis–Task Force on Anticoagulants in Heart Disease. *Thromb Haemost.* (2013) 110:1087–107. doi: 10.1161/THROMAHA.113.00443

19. Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers DRJ. High intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients. *Am J Transplant.* (2016) 16:2954–63. doi: 10.1111/ajt.13803

20. Yin S, Song T, Jiang Y, Li X, Fan Y, Lin T. Tacrolimus trough level at the first month predict renal transplantation outcomes among living chinese kidney transplant patients: a propensity score-matched analysis. *Ther Drug Monit.* (2019) 41:308–16. doi: 10.1097/FTD.0000000000000593

21. O’Seaghdha CM, McQuillan R, Moran AM, Lavin P, Dorman A, O’Kelly P, et al. Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection. *Clin Transplant.* (2009) 23:462–8. doi: 10.1111/j.1399-0012.2009.01021.x

22. Richards KR, Hager D, Muth B, Astor BC, Kaufman D, Djamali A. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. *Transplantation.* (2014) 97:986–91. doi: 10.1097/TP.0000000000000149

23. Pollock-Barziv SM, Finkelstein Y, Manilhot C, Dipchand AI, Hebert D, Ng VL, et al. Variability in tacrolimus blood levels increases the risk of late rejection and graft loss after solid organ transplantation in older children. *Pediatr Transplant.* (2010) 14:968–75. doi: 10.1111/j.1399-3046.2010.01409.x

24. Shihab E, Qazi Y, Mulianoa K, McCague K, Patel D, Peddi VR, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. *Am J Transplant.* (2017) 17:2363–71. doi: 10.1111/ajt.14215

25. Rodrgo E, Segundo DS, Fernndez-Fresnedo G, Lpez-Hoyos M, Benito A, Ruiz JC, et al. Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development. *Transplantation.* (2016) 100:2479–85. doi: 10.1097/TP.0000000000001040

26. Goodall DL, Willcombe M, McLean AG, Taeube D. High intrapatient variability of tacrolimus levels and outpatient clinic nonattendance are associated with inferior outcomes in renal transplant patients. *Transplant Direct.* (2017) 3:e192. doi: 10.1097/TXD.0000000000000710

27. Fulami S, Luciawan M, Hadžiabdić MO, Marušić S, Bačić Vrca V. Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. *Int J Clin Pharm.* (2018) 40:1078–85. doi: 10.1007/s11096-018-0691-z

28. Feng HP, Caro L, Fandozzi CM, Guo Z, Talaty J, Wolford D, et al. Pharmacokinetic interactions between Elbasvir/Grazoprevir and immunosuppressant drugs in healthy volunteers. *Clin Pharmacol.* (2018) 58:666–73. doi: 10.1002/cpdp.1052

29. Zhang H, Bu F, Li L, Jiao Z, Ma G, Cai W, et al. Prediction of drug-drug interaction between tacrolimus and principal ingredients of wuzhi capsule in Chinese healthy volunteers using physiologically-based pharmacokinetic modelling. *Basic Clin Pharmacol Toxicol.* (2018) 122:331–40. doi: 10.1111/bcpt.12914

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Song, Yin, Jiang, Huang, Liu, Wang, Li, Zeng, Fan, Wang, Li and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.